Autistic Disorder Drug Pipeline Market Research Report 2022: Comprehensive Insights About 25+ Companies and 30+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Autistic Disorder – Pipeline Insight, 2022” report has been added to ResearchAndMarkets.com’s offering.

This “Autistic disorder – Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Autistic disorder pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The assessment part of the report embraces, in depth Autistic disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autistic disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Autistic disorder R&D. The therapies under development are focused on novel approaches to treat/improve Autistic disorder.

Autistic disorder Emerging Drugs Chapters

This segment of the Autistic disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Autistic disorder Emerging Drugs

CM-AT: Curemark

CM-AT is designed to enhance protein digestion thereby potentially restoring the pool of essential amino acids. Essential amino acids play a critical role in the expression of several genes important to neurological function and serve as precursors to key neurotransmitters such as serotonin and dopamine. CM-AT, has received “Fast Track” designation from the U.S. Food and Drug Administration (FDA). FDA has also granted Curemark a rolling review of its New Drug Application for CM-AT.

L1-79: Yamo pharmaceuticals

L1-79 is an investigational drug currently in clinical development by Yamo Pharmaceuticals for the treatment of the core symptoms of ASD. L1-79 was granted Fast Track Designation by the Food and Drug Administration in May of 2018. It acts as a tyrosine hydroxylase inhibitor and is expected to modulate the catecholaminergic pathways implicated in ASD. L1-79 reported positive results from Phase II study in November 2021. Clinical studies are planned to further investigate the potential of L1-79 to improve the core symptoms of ASD.

Autistic disorder: Therapeutic Assessment

This segment of the report provides insights about the different Autistic disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Autistic disorder

There are approx. 25+ key companies which are developing the therapies for Autistic disorder. The companies which have their Autistic disorder drug candidates in the most advanced stage, i.e. Preregistration include, Curemark

Phases

This report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Autistic disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Autistic disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Autistic disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Autistic disorder drugs.

Autistic disorder Report Insights

• Autistic disorder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Autistic disorder Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Autistic disorder drugs?
• How many Autistic disorder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Autistic disorder?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Autistic disorder therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Autistic disorder and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Scioto Biosciences
• ACADIA Pharmaceuticals Inc.
• Yamo Pharmaceuticals LLC
• Stalicla SA
• MapLight Therapeutics
• Jazz Pharmaceuticals

Key Products

• SB 121
• Pimavanserin
• FEN164
• L1-79
• ML-004
• GWP42003-P
• STP1

For more information about this report visit https://www.researchandmarkets.com/r/ql4ax

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900